Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detail on financial results, material corporate events, and key regulatory milestones for Syndax’s oncology-focused business.
Recent Forms 8-K filed by Syndax include items on quarterly and year-to-date financial results, where the company furnishes press releases and presentations summarizing revenue from Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), research and development spending, and operating expense trends. Other 8-K filings document significant events such as U.S. Food and Drug Administration approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, as well as board-level changes.
For investors analyzing SNDX, these SEC documents complement earnings press releases and conference call materials by providing standardized, time-stamped records of the company’s disclosures. They help clarify how Syndax reports collaboration revenue from its agreement with Incyte for Niktimvo, how it describes its cash position and funding horizon, and how it characterizes the impact of regulatory approvals on its business.
On Stock Titan, Syndax filings are updated as new documents are posted to EDGAR, and AI-powered tools can assist in navigating complex language, highlighting items related to product approvals, clinical milestones, financial condition, and governance. Users can review 8-Ks for material events, and, where available, refer to 10-K and 10-Q filings for broader discussions of risk factors, pipeline programs, and the company’s description of its commercial-stage biopharmaceutical operations.
Syndax Pharmaceuticals insider Michael A. Metzger filed a notice of proposed sale under Rule 144 to sell 17,159 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $360,826.32. The shares were acquired on 02/06/2026 via restricted stock vesting as compensation. The planned sale is expected around 02/09/2026 on the NASDAQ. Over the prior three months, Metzger sold 7,412 common shares for gross proceeds of $152,836.18, also reported in the filing.
Syndax Pharmaceuticals shareholder files notice to sell shares. A person named Keith A. Goldan filed a Form 144 covering the planned sale of 3,410 shares of common stock through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of 71,706.84 and 86,914,838 shares outstanding.
The shares to be sold were acquired as restricted stock vesting on 02/06/2026 from the issuer as compensation. The form also reports that during the past three months, this person sold 2,082 common shares on 02/06/2026 for gross proceeds of 42,931.05. The filer represents that they are not aware of undisclosed material adverse information about the company.
STATE STREET CORPORATION reported a significant ownership stake in Syndax Pharmaceuticals Inc. common stock. As of 12/31/2025, it beneficially owned 4,596,552 shares, representing 5.3% of the company’s common stock.
State Street reported no sole voting or dispositive power, but shared voting power over 4,341,322 shares and shared dispositive power over 4,596,552 shares. The position is certified as being held in the ordinary course of business and not for influencing control of Syndax.
Syndax Pharmaceuticals Chief Executive Officer and director Michael A. Metzger reported multiple equity transactions. On February 4, 2026, he received 73,000 restricted stock units that vest in three equal annual installments, plus 144,600 performance-based RSUs whose payout depends on pre-set metrics. He was also granted stock options for 440,000 shares at an exercise price of $20.43 per share, vesting monthly over four years. On February 6, 2026, he sold 7,412 shares of common stock at $20.62 per share to cover tax withholding tied to RSU vesting, and after these transactions directly owned 508,849 common shares and 440,000 options.
Syndax Pharmaceuticals Chief Financial Officer Keith A. Goldan reported multiple equity transactions in early 2026. He bought 1,219 shares of common stock on January 30, 2026 at $8.48 per share through the employee stock purchase plan, and now directly holds 143,839 common shares.
On February 4, 2026, he received 21,500 time-based restricted stock units and 30,750 performance-based RSUs, each convertible into one share of common stock upon vesting under service and, for the performance award, metric conditions. He also received 118,000 stock options with a $20.43 exercise price, vesting monthly over four years.
On February 6, 2026, Goldan sold 2,082 shares of common stock at $20.62 per share to cover tax withholding obligations related to RSU vesting, as disclosed, and continues to directly own both common shares and the newly granted options.
Syndax Pharmaceuticals director Jennifer Jarrett received an equity award linked to 24,000 shares of common stock on February 4, 2026. The award is in the form of restricted stock units that vest one year from the grant date.
After this grant, she beneficially owns 114,000 shares of Syndax common stock. The underlying shares cannot be delivered, transferred, or sold until vesting and certain events such as separation from service, death, disability, or a change in control.
Syndax Pharmaceuticals director Martin H. Huber Jr. received an award of 24,000 shares in the form of restricted stock units on February 4, 2026, at a price of $0 per share. After this grant, he beneficially owns 103,000 shares of common stock in direct form.
The restricted stock units vest one year from the grant date. The underlying shares will not be delivered and cannot be transferred or sold until the earlier of a separation from service, death, disability, or a change in control of the company.
Syndax Pharmaceuticals granted equity awards to its Head of R&D and Chief Medical Officer, Nicholas A.J. Botwood, as part of his compensation on 02/04/2026. He received 24,000 time-based RSUs, each representing one share of common stock, which vest in three equal annual installments over three years, contingent on continued service.
He also received 36,000 performance-based RSUs, with shares issuable only if pre-established performance metrics approved by the Compensation Committee are achieved and he remains in service. In addition, he was granted 144,700 stock options with an exercise price of $20.43 per share, vesting in equal monthly installments over four years. All reported common stock awards were acquired at $0 per share, reflecting non-cash equity compensation.
Syndax Pharmaceuticals director Dennis Podlesak reported an equity award on this Form 4. On February 4, 2026, he was granted 48,000 restricted stock units at a price of $0 per share. These units vest one year from the grant date.
The shares underlying the restricted stock units will only be delivered, and may not be transferred or sold, until the earlier of a separation from service, death, disability, or a change in control. After this grant, Podlesak beneficially owns 239,763 shares of common stock, held directly.
Syndax Pharmaceuticals director Aleksandra Rizo reported a grant of 24,000 shares of common stock on February 4, 2026. The award was made at a price of $0 per share and increased her beneficial ownership to 49,000 shares held directly.
The grant represents restricted stock units that vest one year from the grant date. The underlying shares will only be delivered, and therefore cannot be transferred or sold, until the earlier of a separation from service, death, disability, or a change in control.